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Abstract
The identification of a new generation of potent broadly neutralizing HIV-1 antibodies
(bnAbs) has generated substantial interest in their potential use for the prevention and/or
treatment of HIV-1 infection. While combinations of bnAbs targeting distinct epitopes on the
viral envelope (Env) will likely be required to overcome the extraordinary diversity of HIV-1,
a key outstanding question is which bnAbs, and how many, will be needed to achieve opti-
mal clinical benefit. We assessed the neutralizing activity of 15 bnAbs targeting four distinct
epitopes of Env, including the CD4-binding site (CD4bs), the V1/V2-glycan region, the V3-
glycan region, and the gp41 membrane proximal external region (MPER), against a panel
of 200 acute/early clade C HIV-1 Env pseudoviruses. A mathematical model was developed
that predicted neutralization by a subset of experimentally evaluated bnAb combinations
with high accuracy. Using this model, we performed a comprehensive and systematic com-
parison of the predicted neutralizing activity of over 1,600 possible double, triple, and qua-
druple bnAb combinations. The most promising bnAb combinations were identified based
not only on breadth and potency of neutralization, but also other relevant measures, such
as the extent of complete neutralization and instantaneous inhibitory potential (IIP). By this
set of criteria, triple and quadruple combinations of bnAbs were identified that were signifi-
cantly more effective than the best double combinations, and further improved the probabil-
ity of having multiple bnAbs simultaneously active against a given virus, a requirement that
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may be critical for countering escape in vivo. These results provide a rationale for advancing
bnAb combinations with the best in vitro predictors of success into clinical trials for both the
prevention and treatment of HIV-1 infection.
Author Summary
In recent years, a new generation of monoclonal antibodies has been isolated from HIV-1
infected individuals that exhibit broad and potent neutralizing activity when tested against
diverse strains of virus. There is a high level of interest in the field in determining if these
antibodies can be used to prevent or treat HIV-1 infection. Because HIV-1 is adept at
escaping from immune recognition, it is generally thought that combinations of multiple
antibodies targeting different sites will be required for efficacy, much the same as seen for
conventional antiretroviral drugs. How many and which antibodies to include in such
combinations is not known. In this study, a new mathematical model was developed and
used to accurately predict various measures of neutralizing activity for all possible combi-
nations having a total of 2, 3, or 4 of the most promising antibodies. Through a systematic
and comprehensive comparison, we identified optimal combinations of antibodies that
best complement one another for enhanced anti-viral activity, and therefore may be most
effective for the prevention or treatment of HIV-1 infection. These results provide impor-
tant parameters that inform the selection of antibodies to develop for clinical use.
Introduction
The ability to elicit potent broadly neutralizing antibodies through immunization remains an
elusive goal in the development of an effective HIV-1 vaccine [1]. This has motivated major
efforts over the past 6 years to isolate and characterize Env-specific antibodies from HIV-
1-infected individuals who exhibit broad and potent serum neutralizing activity [2–4].
Through technological advances in single cell sorting of antigen-specific memory B cells [5–
11], high-throughput antibody cloning and screening methods, numerous novel monoclonal
antibodies have since been isolated, some of which exhibit exceptional neutralization breadth
and potency when tested in vitro against large panels of diverse HIV-1 isolates [7, 9–20]. Iden-
tification of the epitope targets of these bnAbs has dramatically expanded our knowledge
regarding sites of common vulnerability on the Env spike [21]. Major epitope targets include
the CD4bs [5, 11, 16, 19, 22–27], a glycan-dependent site in variable region 3 (V3) of gp120 [9,
17, 28–31], a V1/V2 glycan-dependent quaternary site on the apex of the Env trimer [9, 10, 12,
32–37], the MPER [15, 38–41], and epitopes bridging both gp120 and gp41 [13, 14, 18, 42].
The hope remains that characterization of these epitope targets and efforts to elucidate the
pathways of bnAb development in vivo will eventually result in the rational design of novel
immunogens and immunization strategies for eliciting such antibodies through vaccination
[12, 16, 24, 43–46]. However, a more immediate potential exists for using bnAbs in clinical set-
tings of passive transfer for the prevention and/or treatment of HIV-1 infection.
In support of preventative modalities, pre-clinical studies in non-human primates (NHP)
have demonstrated that passive transfer of bnAbs can confer sterilizing protection against high
dose mucosal challenges with chimeric simian-human immunodeficiency viruses (SHIVs) [23,
47–53]. Studies in NHP and humanized mice have further investigated the therapeutic poten-
tial of bnAb infusion in the setting of established viral infection, and demonstrated that transfer
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of single bnAbs can result in a transient decline in plasma viremia, reduction of proviral DNA,
and in some cases extended control of viral replication [53–56]. However, viral rebound gener-
ally occurs once the concentration of transferred antibody decays below the therapeutic range,
and the emergence of neutralization resistant escape variants is often observed. Similar obser-
vations were recently described in a phase I clinical study evaluating passive infusion of the
CD4bs bnAb 3BNC117 in HIV-1 infected individuals [57]. While escape from antibody mono-
therapy remains a concern, additional data from animal model studies have shown that thera-
peutic strategies employing combinations of bnAbs to simultaneously target different epitopes
on the Env spike can impede viral rebound and escape, and exert sustained control of viral rep-
lication [53–55]. Thus, for bnAbs to be effectively employed for treatment of HIV-1 infection,
combinations of multiple antibodies will likely be required to confront the extraordinary diver-
sity of the virus and its ability to escape from selective immune pressure.
Recent studies of in vitro neutralization have established that combinations of bnAbs target-
ing distinct epitopes can act in a complementary and additive manner, and exhibit improved
neutralization breadth and potency compared to single bnAbs [58–60]. In the study by Kong
et al., it was shown that the breadth and potency of bnAb combinations could be reliably pre-
dicted using an additive model, with consistent patterns of minor non-additive interactions for
particular bnAb combinations, either antagonistic or synergistic [60]. Certain double, triple
and quadruple bnAb combinations were found to achieve 89 to 100% coverage when tested
against a large diverse multiclade virus panel. However, due to the complementary nature of
the bnAb combinations, in many cases increased breadth was due to only a single bnAb in the
mixture exhibiting neutralizing activity against a given virus. In a clinical setting, such a bnAb
combination would in essence be the equivalent of single antibody monotherapy against a sub-
stantial fraction of viruses, which would have a greater opportunity for escape. Thus, for treat-
ment of HIV-1 infection, it may be advantageous to use bnAb combinations that offer the best
potential for active coverage of most viruses by two or more antibodies.
For bnAb immunotherapy in the setting of chronic infection, viral clearance is the most
desirable outcome, albeit challenging to achieve. Thus, more complex options are being consid-
ered, such as including combinations of the most potent bnAbs together with latency reversing
agents (LRAs) and standard antiretroviral drug treatment [61–63]. For such strategies to be
beneficial, bnAbs will need to be effective at three levels. First, they will need to neutralize the
diversity of viruses circulating in the population targeted for treatment. Second, they will need
to effectively neutralize the complex within-host quasispecies that develop during chronic
HIV-1 infection. And finally, they should be effective against the full spectrum of expressed
forms of Env on any given virion. It has been observed that some bnAbs exhibit neutralization
curves that plateau well below 100% when tested against particular Env pseudoviruses in vitro
[10, 13, 64, 65]. This well-established behavior is surprising given the genetically clonal nature
of viruses used in these assays, and could possibly stem from post-translational variation in the
glycosylation patterns or alternate variable loop and structural configurations of expressed Env
[13, 65–68]. It is a concern that such incomplete neutralization may pose a severe limitation
for achieving the desired therapeutic efficacy in vivo. Thus, an ideal immunotherapy candidate
antibody combination should maximize the genetic and antigenic spectrum of viruses that are
potently neutralized, while minimizing the impact of incomplete neutralization.
A key question that remains is how many bnAbs will be required for long term beneficial
effects in a preventative or therapeutic setting, and which combinations of bnAbs will provide
the most potent and active coverage for testing in human clinical trials. Over the past several
years, multiple bnAbs for each major epitope have emerged as viable candidates based on
extensive in vitro and pre-clinical animal model testing. Given the tremendous resources
required to move even a single candidate bnAb forward into human clinical trials, rational
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decisions must be made to select single antibodies, bivalent antibodies, or components of bnAb
combinations that will theoretically provide the highest potency and coverage against the
diversity of circulating HIV-1. As bnAb clinical efficacy studies are currently being planned for
conduct in southern Africa, coverage and potency of bnAbs against the HIV-1 clade C viruses
that dominate the epidemic in that region is of considerable interest.
Here we utilized a newly described panel of 200 acute/early clade C HIV-1 Env pseudo-
viruses to assess the breadth and potency of 15 of the most promising bnAb candidates target-
ing four major epitopes of HIV-1 Env. A mathematical modeling approach was developed that
increased the accuracy in predicting neutralization titers of bnAb combinations. We experi-
mentally validated the improved accuracy of this model, and then used it to predict the behav-
ior of all possible 2, 3, and 4 bnAb combinations using data derived from single bnAb testing.
Using these predictions, we compared the performance of a comprehensive spectrum of poten-
tial bnAb combinations, and identified those that provide the most optimal potency, breadth,
complete neutralization, and active coverage.
Results
Potency and breadth of single bnAbs against a 200 clade C Env
pseudovirus panel
A panel of bnAbs targeting HIV-1 Env was used to assess and compare the breadth and
potency of neutralization against acute/early clade C Envs. Fifteen bnAbs were selected that
target four distinct epitope regions: the CD4 binding site (CD4bs: 3BNC117, VRC01, VRC07,
VRC07-523, VRC13) [11, 19, 23, 69, 70], the V3-glycan supersite (V3g: 10–1074, 10-1074V,
PGT121, PGT128) [9, 17], the V1/V2-glycan site (V2g: PG9, PGT145, PGDM1400,
CAP256-VRC26.08, CAP256-VRC26.25) [9, 10, 12, 20, 32], and the gp41 MPER epitope
(10E8) [15]. BnAbs were tested against a panel of 200 clade C HIV-1 Env pseudoviruses using
the validated luciferase-based TZM-bl assay. This virus panel consists of viruses isolated from
individuals in the acute/early stages of infection from five southern African countries, includ-
ing South Africa, Tanzania, Malawi, Zambia, and Botswana. Serial dilutions of individual
bnAbs were tested against each virus using a starting concentration that ranged from 10–
50 μg/ml, depending on sample availability at the time of testing. Neutralizing activities were
evaluated using potency-breadth curves (the percentage of viruses neutralized versus an IC50
or IC80 cutoff, Fig 1A and 1B), scatter plots (Fig 1C and 1D) and heatmaps (Fig 1E and 1F).
The 5 bnAbs targeting the V1/V2-glycan region neutralized between 67–75% of viruses with
positive IC50 titers, and the 4 bnAbs targeting V3-glycan neutralized 54–68%. When positive,
these glycan-dependent bnAbs were strikingly potent. Using the more stringent IC80 measure,
median IC80 titers ranged from 0.003–1.274 μg/ml for V1/V2-glycan and 0.073–0.203 μg/ml
for V3-glycan bnAbs (Table A in S1 Text). CD4bs bnAbs tended to exhibit greater breadth
(71–96% at IC50), but were generally less potent than V1/V2-glycan or V3-glycan antibodies
(median IC80 titers 0.30–1.58 μg/ml). The MPER directed bnAb 10E8 exhibited lower overall
potency (median IC80 3.399 μg/ml), yet had exceptional IC50 breadth, neutralizing 98% of
viruses. Even the most resistant isolates were sensitive to at least 3 bnAbs, which most often tar-
geted the CD4bs or MPER. Overall, clear differences in potency and/or breadth were observed
among bnAbs of the same class (defined here as bnAbs that target the same epitope region).
Based on IC50 and IC80 titers, best-in-class bnAbs were CAP256-VRC26.25 (V2-glycan), 10-
1074V (V3-glycan), VRC07-523 (CD4bs), and 10E8 (MPER).
As visualized in heat maps (Fig 1E and 1F), and by hierarchical clustering (Fig A in S1
Text), bnAbs targeting the same epitope region exhibit similar patterns of neutralizing activity,
with clear patterns of complementarity between epitope classes. For example, distinct clusters
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Fig 1. Neutralization activity of bnAbs against clade C virus panel. Potency-breadth curves are presented for both IC50 (A) and IC80 (B) titers. BnAbs are
color coded and grouped by target epitopes. Bold lines indicate bnAbs that were best in class for V2-glycan (V2g), V3-glycan (V3g), CD4bs, and MPER
Optimal bnAb Combinations against HIV-1 Clade C
PLOS Pathogens | DOI:10.1371/journal.ppat.1005520 March 30, 2016 5 / 27
of viruses were resistant to V1/V2-glycan antibodies but sensitive to V3-glycan antibodies,
whereas other virus clusters exhibit the opposite phenotype. These data illustrate how different
combinations of bnAbs targeting distinct epitopes can complement one another for enhanced
coverage against clade C viruses.
Accurate prediction of bnAb combination neutralization using single
bnAb neutralization data
Because it is not practical to assay all combinations of bnAbs against a large panel of viruses, a
new method to accurately predict combination bnAb neutralization efficacy using the available
large-scale single bnAb neutralization data was developed to facilitate rational decisions for
selection of the best bnAb combinations for clinical testing.
In a previous study by Kong et al., the additive model worked well in predicting potency of
bnAb combinations using experimental data from single bnAbs [60]. They also found that the
experimental bnAb combination data deviated slightly from model predictions. Most combina-
tions performed slightly better than predicted, while a few combinations that included a
V3-glycan bnAb performed slightly worse than predicted. The additive model derives from an
application of equilibrium mass action kinetics to simplified in vitro antibody-virus interac-
tions (S1 Text). This theoretical treatment assumes that single bnAb neutralization curves fol-
low Hill curves with Hill exponents equal to one, and that antibodies act independently with
little possibility of multiple antibodies inhibiting the same virion. The first assumption of a unit
Hill exponent is largely valid for CD4bs and V3-glycan bnAbs, however, bnAbs targeting the
V2-glycan and MPER epitopes frequently exhibit Hill exponents of less than 1 [65, 71, 72].
To overcome these limitations of the additive model, we developed a new model, the “Bliss-
Hill model” (BH model). This model combines single bnAb Hill curves (with arbitrary slopes)
within the framework of the Bliss independence model for the binding of multiple species of
ligands to a substrate [72, 73], and incorporates a correction for multiple ligands independently
attaching to the substrate (S1 Text). We tested the BH model by using experimental data from
combination bnAb neutralization assays. The assays comprised 10 combinations of 2, 3 and 4
bnAbs (including 2-bnAb combinations with both antibodies targeting similar epitopes, Fig B
in S1 Text) assayed against a smaller panel of 20 viruses. The 20 viruses were chosen because
they are sensitive to almost all bnAbs tested and comprise a maximized range of IC80 titers for
the bnAb combinations. The BH model proved highly accurate in explaining the clade C panel
bnAb combination data (Fig 2A, R2 = 0.9154, Pearson r = 0.9584). Moreover, the BH predic-
tions were closer to the observed data than the additive model for 9 of the 10 combinations
tested (Fig 2B, p = 0.021 using Binomial Test), with the only exception being the combination
VRC07-523 + 10-1074V. Thus the BH model offered a significant, though modest in magni-
tude, improvement in prediction accuracy over the additive model. We confirmed this by rean-
alyzing a larger dataset from Kong et al., and again found the BH model predictions to be
highly accurate (R2 = 0.9655, Pearson r = 0.9862, Fig C in S1 Text). The BH model performed
slightly better than the additive model in all cases, and the difference reached high levels of sta-
tistical significance for most of the 2, 3, and 4 bnAb combinations tested. This improvement
was due to the systematic trend of BH predictions being more potent than the additive model
epitopes. Dashed vertical lines indicated the lowest and highest concentration tested. Neutralization data are also presented as scatter plots of IC50 (C) and
IC80 (D) titers in which each virus is represented by an individual dot. The highest concentration tested for each bnAb and the percentage of viruses
neutralized are indicated. Solid bars represent median titers. Heat maps of IC50 (E) and IC80 (F) were generated using the Heatmap tool on the Los Alamos
HIV Database. In the heatmaps, rows represent viruses, and columns represent bnAbs. The darker hues indicate more potent neutralization, and blue (for
contrast) indicates the virus had IC50 or IC80 above threshold, unable to reach this level of neutralization at the highest concentration of bnAb tested. The
order of viruses is same in panels E and F.
doi:10.1371/journal.ppat.1005520.g001
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predictions (Figs D and E in S1 Text), and thus closer to the observed titers since additive
model predictions were found to be less potent than the observed titers for most combinations
[60].
Nonetheless, for some antibody combinations, experimentally measured IC80 titers still
showed minor deviations from the BH model predictions (Fig 2, Figs C-G in S1 Text). For a
few viruses, the combination IC80 titers were 3-fold higher than the most potent bnAb in the
combination (Fig D in S1 Text), which is counter-intuitive since both the additive and BH
models predict greater potency for combinations relative to the component bnAbs. In such
cases we find that the very potent neutralization of a virus by an antibody (particularly
CAP256-VRC26.25, Fig D in S1 Text) is somewhat inhibited by the presence of additional anti-
bodies, albeit still resulting in potent neutralization by the combination. Models that incorpo-
rated additional parameters based on observed deviations could further improve predictions in
some cases (S1 Text, Figs F and G in S1 Text), but the magnitude of deviations were small for
most viruses. Furthermore, using deviation modeling with BH model (Fig H in S1 Text) or
using additive model (Fig I in S1 Text) did not affect the conclusions below, as the best combi-
nations selected were robust using either model.
Fig 2. Comparison of Additive and Bliss-Hill models for predicting bnAb combination neutralization scores. Additive and Bliss-Hill models were used
to analyze bnAb combination IC80 scores for the Clade C Panel. In (A), BH model predictions are plotted against observed IC80 values for 20 viruses, with
different bnAb combinations (n = 10) shown by different colors and/or symbols. (B) For each bnAb combination tested, the absolute difference between the
predicted and the observed Log10 IC80 values for each virus was calculated using both BH and additive models (Fig D in S1 Text). Median Log10 differences
using BHmodel are shown as blue bars and using additive model are shown as green bars, with vertical grey bars representing half the interquartile range.
Wilcoxon paired rank test was used to determine whether the Bliss Hill model provides a statistically significantly smaller prediction error for this panel of
viruses. Fig D in S1 Text illustrates each of the paired model predictions for the Envs and antibody combinations tested. The additive model often slightly
underestimates the observed combination potency, while BHmodel estimates are closer to the observed. Combinations of bnAbs for which the p-value was
smaller than the threshold established by a false discovery rate of q<0.1 are indicated. See Figs C and E in S1 Text for equivalent analysis using the Kong
et al. dataset [60].
doi:10.1371/journal.ppat.1005520.g002
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Comparison of neutralization potency and breadth for all potential 2, 3,
and 4 bnAb combinations
Passive and active immunization strategies that aim to protect against the acquisition of HIV-1
infection would benefit from information regarding how many and which bnAb combinations
provide optimal coverage and potency. An antibody that may have the best characteristics
when considered alone may not have the optimal complementarity when considered for com-
bination bnAb regimens. We predicted the combination scores for all potential 2, 3 and 4
bnAb combinations using the BH model on single bnAb neutralization data for 15 bnAbs
against 200 clade C viruses, thus enabling direct comparisons of bnAb combinations. For 2
bnAb combinations, only combinations consisting of bnAbs targeting different epitopes were
considered, while for 3 and 4 bnAb combinations, multiple bnAbs targeting the same epitope
region were also considered. Predicted potency-breadth curves for all of the 2, 3 and 4 bnAb
combinations (1,622 combinations total) are shown in Fig 3.
The combinations were stratified by the number of bnAbs targeting different epitopes
(referred to as “categories”, e.g., CD4bs+V2g is a combination of a CD4bs and a V2-glycan
Fig 3. BH predicted IC80 potency-breadth curves scores for all candidate 2, 3 and 4 bnAb combinations against the clade C virus panel. Potency-
breadth curves for all candidate 2 (A), 3 (B) and 4 (C) bnAb combinations are shown for a total of 1,622 bnAb combinations (81 double-, 431 triple-, 1,110
quadruple-bnAb combinations), using BHmodel predicted IC80 scores. Each combination’s potency-breadth curve is color coded according to the number of
bnAbs of different specificities in the combination, e.g. all 4-bnAb combinations that had two V2g bnAbs, and 1 each of other specificities, were assigned to
the same category and were color coded blue in (C). The best-in-category bnAb combinations are highlighted in darker colors in A-C, and the others are
shown by matched lighter colors. In (B) and (C), “0/1” indicates combinations in which the indicated epitope may or may not have been covered by a
representative bnAb. Combinations with a given total number of bnAbs that have 2 bnAbs targeting a single epitope and up to one bnAb targeting other
epitopes were grouped together into categories. Such categories are represented as e.g. “2 CD4bs + 0/1 V2g + 0/1V3g + 0/1 MPER” in the figure, which in
the case of 4 bnAb combinations, are composed of combination types “2 CD4bs + V2g + V3g”, “2CD4bs + V2g + MPER” and “2CD4bs + V3g + MPER.
doi:10.1371/journal.ppat.1005520.g003
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bnAb, and V2g(2x)+V3g has two V2-glycan and one V3-glycan bnAbs). Within each category,
multiple combinations were possible due to multiple bnAbs targeting the same epitope. Best-
in-category bnAb combinations were identified as those with the lowest geometric mean IC80
values for the 200 viruses (highlighted in Fig 3 by dark, bold lines). Of note, the area under the
IC80 potency-breadth curve is negatively, but linearly, and almost perfectly correlated to the
Log10 geometric mean IC80. Thus using either measure gives identical results. The best-in-cate-
gory combinations were not always clear, as second best combinations were very comparable
(e.g. CAP256-VRC26.25 + 10-1074V + PGT128 or PGT121 with geometric mean IC80 of 0.007
and 0.0071μg/ml, respectively). Comparisons of best-in-category combinations having the
same number of bnAbs are shown in Fig 4.
Best-in-category 2 bnAb combinations had significantly better predicted potency (geomet-
ric mean IC80 range = 0.02–0.29 μg/ml) and breadth (88.5–97.5% of viruses with IC80 < 10 μg/
ml), than single bnAbs (geometric mean IC80 = 0.17–5.91 μg/ml and breadth = 44–92.5%). The
two best-in-category 2 bnAb combinations, CAP256-VRC26.25 (V2-g) with either 10-1074V
(V3-g) (geometric mean IC80 = 0.020 μg/ml) or VRC07-523 (CD4bs) (geometric mean IC80 =
0.021 μg/ml) were significantly better than the other best-in-category 2 bnAb combinations
Fig 4. Comparison of best-in-category bnAb combinations for potency and breadth of neutralization.Comparisons of best combinations from each
category within the 2- (A-C), 3- (D-F) and 4- (G-I) bnAb combinations are presented. Shown below each combination are its geometric mean and median IC80
titer and the percent viral coverage at IC80 < 10 μg/ml (A, D, G). Combinations are ordered using geometric mean IC80 titers, and a combination is indicated
as better than (‘>‘) the proceeding combination when the difference in geometric mean IC80 exceeded 0.001 μg/ml, otherwise it is indicated as similar (‘~’).
The distributions of IC80 scores for the best combinations were compared using a Wilcoxon Rank Sum Test, and only those p-values with q-value < 0.1 are
shown. Potency-breadth curves (B, E, H) and distributions of IC80 values (C, F, I) for the top 2 combinations are shown. Grey lines in C, F, I connect the
predicted IC80 values for the same virus.
doi:10.1371/journal.ppat.1005520.g004
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(p< 0.01 and q-value< 0.02) (Fig 4A, 4B and 4C). However, it was unclear which of these two
combinations was better, because each pairing had different advantages. While
CAP256-VRC26.25 and 10-1074V alone are more potent than VRC07-523 when active
(Table A in S1 Text), they have more limited breadth, each neutralizing ~60% viruses at IC80<
10 μg/ml as compared to 92.5% for VRC07-523. Consistent with this, we found that the combi-
nation of CAP256-VRC26.25 + 10-1074V missed ~13% of viruses at IC80< 10 μg/ml, while
CAP256-VRC26.25 + VRC07-523 missed only ~3%. Thus, while CAP256-VRC26.25
+ VRC07-523 was slightly less potent than CAP256-VRC26.25 + 10-1074V, it provides ~10%
better coverage.
For 3 bnAb combinations, the best breadth and potency was seen with CAP256-VRC26.25
+ 10-1074V + VRC07-523 (Fig 4D, 4E and 4F). This combination, which targets 3 separate epi-
topes, neutralized 99.5% viruses (all but one in the panel) at IC80< 10 μg/ml, with a geometric
mean IC80 of 0.0083 μg/ml. The superior performance of this combination draws from the
complementary neutralization profiles of the most potent panel bnAbs, CAP256-VRC26.25
and 10-1074V, combined with the broad and potent profile of VRC07-523 (Fig 1). This combi-
nation was significantly more potent than most other best-in-category 3bnAb combinations
(p< 0.02, q< 0.03). Replacing VRC07-523 with either PGDM1400 or 10E8 in combinations
containing CAP256-VRC26.25 + 10-1074V resulted in a small loss of potency and breadth that
was not statistically significant. Overall, 3 bnAb combinations showed improved breadth (89 to
99.5% at IC80< 10 μg/ml) and markedly improved potency (geometric mean IC80 of 0.008–
0.060 μg/ml) than 2 bnAb combinations, with 6 out of 7 best-in-category 3 bnAb combinations
predicted to have better geometric mean IC80 than the best 2 bnAb combinations.
The two best-in-category 4 bnAb combinations, one targeting 3 epitopes and another tar-
geting 4 epitopes, had comparable potency (geometric mean IC80 ~ 0.007 μg/ml) and breadth
(99.5% at IC80 < 10 μg/ml) (Fig 4G, 4H and 4I), and were more potent and broadly active than
4 bnAb combinations targeting only 2 epitopes (geometric mean IC80 of 0.01 to 0.05 μg/ml and
breadth 92–98.5% at IC80 < 10 μg/ml). Thus bnAb combinations targeting three epitopes
showed a significant gain in breadth and potency compared to those targeting two, but the fur-
ther gain in targeting all four major epitopes, for this panel is negligible. This information is
useful to efforts that aim to achieve optimal coverage and potency to protect against the acqui-
sition of infection in passive or active vaccination settings, but does not take into account ease
of escape in the setting of passive immunotherapy for active infection.
Breadth of neutralization by multiple active bnAbs in combination
Combinations of bnAbs are likely to be advantageous in a therapeutic setting not only to maxi-
mize potency and breadth but also to minimize the potential for viral escape by targeting multi-
ple epitopes simultaneously [55]. Thus, we investigated the extent of simultaneous
neutralization by two or more bnAbs in the best-in-category bnAb combinations at different
activity thresholds.
First we quantified the percent of panel viruses actively neutralized by at least 2, 3 or 4
bnAbs in all best-in-category 2, 3 and 4 bnAb combinations at physiologically relevant concen-
trations. We used IC80 thresholds of 1, 5 and 10 μg/ml, which fall in the range of bnAb serum
concentrations in HIV-1 infected patients administered a single dose of 1–30 mg/kg of
3BNC117 [57]. For combinations with multiple bnAbs targeting the same epitope class, a mod-
ified counting procedure was employed that accounted for overlap in escape-associated muta-
tions (S1 Text). The percent of viruses neutralized by the best bnAb combinations at different
thresholds of activity are shown in Table B in S1 Text. We modified the potency-breadth curves
for best-in-category bnAb combinations to highlight cases where multiple bnAbs in a
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combination were simultaneously active (Fig 5). These curves show cumulative coverage of the
200 panel viruses at a given predicted combination IC80 value limited by counting only those
viruses that were simultaneously sensitive to 2, 3 or 4 bnAbs at single bnAb IC80 < 1, 5, or
10 μg/ml.
When the percentage of viruses neutralized by at least 2 bnAbs was considered, the best cov-
erage at our least restrictive threshold within the experimental assay range of IC50 <10 μg/ml
was 92.5%, 97.5% and 100% for 2, 3 and 4 bnAb combinations, respectively (Table B in S1
Text, Fig 5). This coverage decreased, as expected, to 80%, 91% and 95.5%, respectively, when a
more stringent IC80 <10 μg/ml threshold was used, and continued to decrease until only 44%,
67.5% and 73.5% coverage was seen, respectively, at our most stringent threshold of IC80
<1 μg/ml. The percentage of viruses neutralized when requiring at least three bnAbs in the
best-in-category 3 and 4 bnAb combinations to be active was of course even lower at each of
these thresholds. Here, the best coverage at the less restrictive threshold of IC50 <10 μg/ml was
66.5% and 89% for 3 and 4 bnAb combinations, respectively, and progressively decreased to
only 19.5% and 26.5% coverage at the most stringent IC80<1 μg/ml threshold. Poor coverage
was seen at all thresholds when all 4 bnAbs in the best-in-category 4 bnAb combinations were
required to be active.
Fig 5. Extent of neutralization by multiple active bnAbs from best-in-category combinations.Modified IC80 potency-breadth curves are shown for best-
in-category 2, 3, and 4 bnAb combinations. These modified curves measure the fraction of all 200 viruses that are neutralized at predicted combination IC80
values, but limited by counting only those viruses that were simultaneously neutralized by at least 1, 2 or 3 bnAbs in the combination. Potency-breadth curves
are shown for the best 2 bnAb combinations in which at least 1 or 2 bnAbs were required to be simultaneously active at IC80 thresholds of <1 μg/ml, 5 μg/ml or
10 μg/ml (A). Similar potency-breadth curves are shown for the best 3 bnAb (B) or 4 bnAb (C) combinations in which at least 2 or 3 bnAbs were required to be
simultaneously active at these IC80 thresholds. The modified potency-breadth curves in this figure do not reach the indicated IC80 thresholds when 2 or more
bnAbs are required to be active because the curves are driven by the IC80 value of the more potent active bnAb in the combination, which is often much lower
than the activity threshold IC80.
doi:10.1371/journal.ppat.1005520.g005
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Using extrapolated single bnAb neutralization curves (see “BnAb combinations reduce lev-
els of incomplete neutralization” below), we also investigated coverage with multiple active
bnAbs using single bnAb IC80< 50 μg/ml and< 100 μg/ml (Fig J in S1 Text). These concentra-
tions roughly approximate the 28 day trough plasma concentrations of passively-administered
VRC01 and 3BNC117 in human trials [57, 74] and more closely approximate the range of
plasma concentrations that resulted in transient reductions in plasma viremia in patients who
received 3BNC117 [57]. We found that the best coverage with 2 bnAbs active at IC80 <50–
100 μg/ml was 93–100% for 2, 3 and 4 bnAb combinations, and with 3 bnAbs active was 68–
92.5% (Fig J and Table B in S1 Text). The overall most potent and broad 2, 3, and 4 bnAb com-
binations (Fig 4), also had best or close to best coverage with multiple bnAbs active (Fig 5).
However, best-in-category combinations that included the exceptionally broad but less potent
10E8 showed superior coverage with multiple bnAbs active at less restrictive thresholds.
BnAb combinations reduce levels of incomplete neutralization
Neutralization curves for some bnAb/virus pairings can show incomplete neutralization of the
genetically clonal virus population [65]. This suggests that a sub-population of virus is resistant
to neutralization by the bnAb even at the highest concentrations tested. Given the importance
of carbohydrates for many bnAb epitopes, post-translational glycan heterogeneity resulting
from incomplete carbohydrate addition or modification may be an important contributing fac-
tor to such resistant sub-populations [68]. The inability to neutralize all variants would com-
promise the use of bnAbs for immunotherapy and may also impede the ability of bnAbs to
protect against HIV acquisition. Hence, we investigated the extent of incomplete neutralization
of clonal viruses by various bnAb combinations.
We first analyzed neutralization curves for single bnAbs and bnAb combinations that were
experimentally measured in the study by Kong et al. [60]. We could accurately predict the combi-
nation maximum percent inhibition (MPI) using the Bliss independence model on single bnAb
MPI values (Methods, Fig K in S1 Text, Pearson r = 0.9904, difference between observed and pre-
dicted MPI: median = 0.1%, 95% CI = 0–4.5%). Using this model, we then predicted the MPI val-
ues for the 2, 3 and 4 bnAb combinations composed of the best single bnAbs against the clade C
panel. Experimental MPI values for single bnAbs are shown in Fig 6A (see S1 Text for discussion
on different assay starting concentrations for panel bnAbs), and the predicted MPI values for 2, 3
and 4 bnAb combinations are shown in Fig 6B, 6C and 6D, respectively.
Incomplete neutralization was observed against several viruses for all single bnAbs and was
frequent for the V2- and V3-glycan bnAbs CAP256-VRC26.25 and 10-1074V, (56% and 44%
viruses with MPI< 95%, respectively). A lower frequency of incomplete neutralization was
observed with VRC07-523 (11% viruses with MPI< 95%) and 10E8 (16.5%). Encouragingly,
the fraction of resistant variants within a single virus preparation was predicted to decrease
with increasing number of bnAbs in a combination, indicating that bnAbs tend to be comple-
mentary not only in terms of viral sensitivity at the population level, but in terms of the resis-
tant subpopulations of post-translational Env variants. The 2 bnAb combination with the least
fraction of viruses incompletely neutralized was VRC07-523 + 10E8 (2%), while VRC07-523
+ CAP256-VRC26.25, which had one of the best potency and breadth profiles, had 4% viruses
with MPI< 95%. Consistent with the high levels of incomplete neutralization seen with the
V2- and V3-glycan bnAbs, a higher extent of incomplete neutralization was predicted for
CAP256-VRC26.25 + 10-1074V, where MPI<95% was seen for 18% of viruses. Strikingly, the
3 bnAb combinations had MPI< 95% for only 0.5–1% viruses (n = 1–2 out of 200), and the 4
bnAb combination never had MPI< 95% for any virus. The analysis of experimentally mea-
sured MPI from the Kong et al. study also showed similar patterns (Fig L in S1 Text).
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Studies of passive bnAbs in humans aim to achieve plasma concentrations that for periods
of time exceed 25 μg/ml, a dose commonly tested in our neutralization assays [60]. We there-
fore experimentally tested the extent of incomplete neutralization at concentrations of up to
100–200 μg/ml against a subset of 24 viruses that were selected based on incomplete neutraliza-
tion at the lower doses tested (Fig M in S1 Text). Most of these viruses were still incompletely
neutralized at the highest concentrations tested (only 1 out of 24 showed 95% or higher neu-
tralization). We then estimated the best-fit Hill curves using data points below 25 μg/ml (Meth-
ods, S1 Text) and used these to predict neutralization at the highest concentrations tested for
each of these high-concentration assays. The predictions were quite accurate (average root
mean square error = 6%, Kendall Tau p = 3.7 x 10−5, Fig N in S1 Text). Thus, using this
approach, we predicted the MPI at 100 μg/ml for all best-in-class bnAbs (Fig N in S1 Text) and
their combinations (Fig O in S1 Text) for all 200 clade C panel viruses. As expected, the frac-
tion of viruses with predicted neutralization less than 95% at 100 μg/ml was reduced compared
to the values at 25 μg/ml. Still, we found substantial levels of incomplete neutralization at
Fig 6. MPI exhibited by single bnAbs and bnAb combinations. The observed MPI for single bnAbs (A) and predicted MPI values for 2, 3 and 4 bnAb
combinations (B-D) are shown. Vertical lines indicate each of the 200 panel viruses and are ordered by MPI values for CAP256-VRC26.25 in all panels. For
each virus, the MPI for a bnAb or a bnAb combination is represented by a symbol as shown to the right. The percentage of viruses with MPI <95% for each
bnAb and bnAb combination is also indicated.
doi:10.1371/journal.ppat.1005520.g006
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100 μg/ml and these results qualitatively recapitulated the above patterns of MPI at 25 μg/ml
for single bnAbs and for bnAb combinations.
Instantaneous inhibitory potential of bnAb combinations
The metric instantaneous inhibitory potential (IIP) measures the log10 reduction in a single
round of infection events in the presence of a drug. This metric correlates with clinical success
of antiretroviral drug combinations, and can be used to characterize their efficacy [75]. Jilek
et al. found that IIPave values (average IIP during the dosing interval, given drug pharmacoki-
netics) of 5–8 logs were necessary for successful antiretroviral therapy. Drug combinations in
this range showed a reduction of viral load to<50 RNA copies/ml at 48 weeks in 70% or more
of infected individuals. Applying their approach, we calculated the IIP values for the best-in-
class single bnAbs and best bnAb combinations for the clade C panel.
IIP values for single bnAbs were calculated using either the best-fit Hill curves of experi-
mental neutralization data for the best-in-class bnAbs (Fig 7, S1 Text), or estimated Hill curves
using IC50 and IC80 values (Fig P in S1 Text) (with the former expected to yield more accurate
predictions since IIP values are critically sensitive to neutralization close to 100%). Using BH
model, we calculated the IIP values (Methods) for 2, 3 and 4 bnAb combinations of the best-in-
class bnAbs (Fig 7). Since IIP values depend on bnAb concentration, and precise doses and
pharmacokinetics of bnAbs are still being established, we analyzed IIP at bnAb concentrations
of 1, 10 and 100 μg/ml. The 1 and 10 μg/ml concentrations are within the experimental assay
range, whereas results for the 100 μg/ml dose are estimates obtained by extrapolation.
The best-in-class single bnAbs had median IIPs of 0.4–2.8 across viruses, depending on the
bnAb and concentration, with CD4bs bnAb VRC07-523 giving the highest value, followed by
V3-glycan bnAb 10-1074V (Fig 7, Fig P in S1 Text). The best-in-category bnAb combinations
showed higher median IIP values of 1.2–5.0, 2.3–6.6, and 3.5–8.1 for 2, 3 and 4 bnAb combina-
tions, respectively. The 2 bnAb combinations with highest IIP values consisted of VRC07-523
with either CAP256-VRC26.25 or 10-1074V, depending on the concentration. The 3 bnAb
combinations with the highest IIP values were VRC07-523 + 10-1074V with either
CAP256-VRC26.25 or 10E8, with the latter combination having a slightly better median IIP at
100 μg/ml (median IIP of 6.2 and 6.6, respectively).
Single bnAbs rarely had IIP> 5, the level found to be critical for clinical success of antire-
troviral drug combinations [75], while 2, 3 and 4 bnAb combinations had IIP> 5 for 0–50%,
1.5–79%, and 15–92% of viruses, respectively, depending on concentration. The median IIP of
the best 3 bnAb combinations exceeded 5 only at 100 μg/ml, while the best 4 bnAb combina-
tion had median IIP> 5 at a lower concentration threshold of 10 μg/ml. The range of median
IIP values for the best 4 bnAb combination (3.5–8.1) is comparable to the average IIP for some
of the currently prescribed antiretroviral triple-drug combinations (IIP ~ 3.5–12) [75].
Comparison between the best 2, 3, and 4 bnAb combinations
We next systematically compared the best-in-category 2, 3, and 4 bnAb combinations to evalu-
ate the benefit of having combinations with more total antibodies on overall performance
using the metrics described above; namely the overall potency-breadth curves (Figs 3 and 4),
the number of active bnAbs in the combination (Fig 5), the extent of incomplete neutralization
(Fig 6), and IIP values (Fig 7). The relative impact of these metrics on clinical success is
unknown and the relevance of each metric might differ for prevention versus treatment of
HIV-1 infection, e.g. neutralization by multiple active bnAbs and IIP may be more relevant for
latter. Working under the a priori hypothesis that an ideal combination should maximize per-
formance using all four metrics, we chose VRC07-523 + CAP256-VRC26.25, VRC07-523
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+ CAP256-VRC26.25 + 10-1074V and VRC07-523 + CAP256-VRC26.25 + 10-1074V + 10E8
as the best 2, 3, and 4 bnAb combinations for comparison, respectively. These combinations
showed best or near best performance using all four metrics when compared with other combi-
nations with same number of bnAbs.
Using overall potency and breadth profiles, the best 3 and 4 bnAb combinations were signif-
icantly more potent than the best 2 bnAb combination, with a 2.6–3.1-fold more potent geo-
metric mean IC80 (Fig 8A, p< 0.0014), and showed higher breadth of 97–99% versus 87%
viruses neutralized at IC80 < 10 μg/ml, respectively. The best 3 and 4 bnAb combinations also
demonstrated superior performance over the best 2 bnAb combination in limiting the extent of
incomplete neutralization (Fig 8B). The fraction of viruses predicted to have< 95% neutraliza-
tion at 10 μg/ml for 3 (1.5% viruses) and 4 bnAbs (0.5% viruses) was significantly lower than
that for 2 bnAbs (8% viruses, p< 0.0036). Similarly, IIP for 3 and 4 bnAb combinations were
significantly higher than the 2 bnAb combination (Fig 8C, p< 2.5 x 10−16), and showed signifi-
cantly higher fraction of viruses above the clinically relevant threshold of 5 (p< 1.2 x 10−10,
Fisher’s exact test). The best 3 and 4 bnAb combinations also showed significant improvement
of coverage with at least 2 bnAbs active (Fig 8D and 8G, 28–42% improvement in coverage,
p< 7.7 x 10−10). The main reason behind the poor coverage of viruses neutralized by 2 bnAbs
in the best 2-bnAb combination was the limited breadth of CAP256-VRC26.25, which was
included for its potency when positive (Fig 8E–8G).
Four bnAbs were predicted to be similar to 3 bnAbs by some metrics, and significantly bet-
ter by others. The best 3 and 4 bnAb combinations showed nearly identical distributions of
IC80 values (Fig 8A), and levels of incomplete neutralization (Fig 8B). In contrast, the best 4
bnAb combination showed significantly higher coverage than the best 3 bnAb combination for
both neutralization by at least 2 active bnAbs (improvement in coverage 9.5% using activity
threshold of IC80 < 10 μg/ml, p = 0.0001), and by at least 3 active bnAbs (improvement in cov-
erage 47%, p = 1.9 x 10−21, Fisher’s exact test) (Fig 8D and 8G). Also potentially relevant for
success in therapeutic settings, the best 4 bnAb combination showed significantly higher IIP
scores (Fig 8C, p = 8.9 x 10−9) and significantly higher number of viruses with IIP> 5 than the
best 3 bnAb combination (25% more viruses, p = 8.5 x 10−7). These results indicate that 4
bnAb combinations may be more effective in preventing viral escape compared to 3 bnAb
combinations.
Discussion
The exceptional breadth and potency of a new generation of bnAbs offers new clinical opportu-
nities for the prevention and/or treatment of HIV-1 infection. Two CD4bs bnAbs, VRC01 and
3BNC117, have already initiated phase I clinical testing in infected subjects, and efficacy studies
for the prevention of HIV-1 infection are planned [57, 74]. The most effective approaches will
likely employ combinations of bnAbs targeting multiple epitopes on HIV-1 Env to maximize
potency and coverage and to impede escape, which may be particularly important in the case
of immunotherapy. Prevention of sexual transmission of HIV-1 may represent a relatively eas-
ier target for success, as bnAbs at mucosal surfaces at the time of exposure need only to block
the infecting virus, while therapeutic approaches need to contend with high levels of replicating
virus, complex within-host viral diversity, and established latent viral reservoirs. Given the
large number of bnAbs now available against multiple epitope regions of HIV-1 Env, it is of
Fig 7. IIP for bnAbs and bnAb combinations. IIP values (log10 reduction) are shown for the best-in-class single bnAbs and their combinations at 1 μg/ml
(A), 10 μg/ml (B) and 100 μg/ml (C). In each panel, numbers in the top row showmedian IIP values and in the bottom row show the percentage of viruses with
IIP > 5. The dotted horizontal lines are at IIP = 5.
doi:10.1371/journal.ppat.1005520.g007
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great interest to have experimental measures and predictive models that can be used for evalu-
ating and selecting optimal combinations of bnAbs for clinical development for the prevention
and/or treatment of HIV-1 infection.
Among the bnAbs tested here, the best-in-class single bnAbs for potency and breadth
against our panel of 200 clade C viruses were CAP256-VRC26.25 (V2-glycan), 10-1074V
(V3-glycan) and VRC07-523 (CD4bs) (Fig 1). While 10E8 was the only MPER-directed bnAb
tested, it was previously shown to be the most broadly reactive and potent of the known MPER
bnAbs against other virus panels [15]. To evaluate various combinations of bnAbs we devel-
oped a new model, the Bliss Hill (BH) model, and found it to more accurately predict the
breadth and potency of antibody combinations than the additive model (Fig 2, Fig C in S1
Text). We applied the BH model to predict neutralization profiles of over 1,600 possible 2, 3,
and 4 bnAb combinations against the 200 clade C viruses using experimental data from the
testing of single bnAbs alone (Figs 3 and 4). These predictions allowed us to identify and com-
pare best-in-category bnAb combinations. The overall potency and breadth of neutralizing
activity significantly improved as the total number of bnAbs in the combination was increased
from 2 to 3, but not from 3 to 4 (Figs 4 and 8). Two best 2 bnAb combinations were identified
that demonstrate superior performance in overall potency and breadth. While
CAP256-VRC26.25 + 10-1074V was slightly more potent than CAP256-VRC26.25 + VRC07-
523, the latter combination exhibited better breadth, and thus may be preferred. The best 3
bnAb combination (CAP256-VRC26.25 + VRC07-523 + 10-1074V) benefitted from combin-
ing the complementary potent profiles of CAP256-VRC26.25 and 10-1074V, with the added
potency and breadth of VRC07-523. The best 4 bnAb combinations were significantly better
than the best 2 but not 3 bnAb combinations. Together, these results demonstrate the substan-
tial benefit bnAb combinations afford when selected to complement and optimize target epi-
topes, potency, and breadth of coverage. These parameters will be important to consider when
selecting bnAb combinations for both prevention and immunotherapy of HIV-1 clade C
infection.
We note that 8 of the 15 bnAbs tested here did not show up as a component of best combi-
nations. In most cases these bnAbs exhibited weaker potency and breadth of neutralization
than bnAbs in the corresponding epitope class that did show up (Fig 1A). An exception is
VRC07, which had a better profile than 3BNC117, yet 3BNC117 and not VRC07 showed up as
a component of best combinations. Another exception is PGT121, which was marginally better
than PGT128, yet PGT128 and not PGT121 showed up in best combinations. In both of these
cases the bnAb in best combinations (3BNC117 and PGT128) had slightly greater potency
against sensitive viruses (Table A in S1 Text).
Our analyses further highlight that bnAb combinations, especially those to be used for treat-
ing established HIV-1 infection, can be selected to increase the probability of having at least
two antibodies in the mixture active against a patient’s virus. While having an increased num-
ber of active bnAbs in a combination is desirable, our results illustrate the sobering limitations
with even the best bnAbs currently available (Figs 5 and 8). For IC80 thresholds of 1–10 μg/ml,
Fig 8. Comparison of best 2, 3 and 4 bnAb combinations. (A) Potency-breadth curves for the best combinations are shown. IC80 scores for combinations
were compared usingWilcoxon rank sum test. (B) Fraction of viruses (total n = 200) predicted to have < 95% neutralization at 10 μg/ml for the best
combinations. Fisher’s exact test was used to calculate the statistical significance. (C) IIP calculated at 10 μg/ml for the best combinations against each of the
200 panel viruses. Statistical significance of the difference in IIP values was found using Wilcoxon rank sum test. (D) Fraction of viruses neutralized by at
least 2 bnAbs in the best combinations at single bnAb IC80 thresholds of < 10 μg/ml. Fisher’s exact test was used to calculate statistical significance. (E, F, G)
show heatmaps of IC80 values for the best single bnAbs and the best bnAb combinations respectively. Rows represent viruses, and columns represent single
and combination bnAbs. Same ordering of viruses is used in E-G. Darker hues of red indicate more potent neutralization and grey cells indicate IC80 above
threshold. In (G), blue shades indicate viruses that were neutralized by less than 2 bnAbs (left panel) or by less than 3 bnAbs (right panel) at single bnAb at
IC80 < 10 μg/ml.
doi:10.1371/journal.ppat.1005520.g008
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the percentage of clade C viruses neutralized was reduced to 44–95.5% when requiring a mini-
mum of 2 bnAbs in the combination to be active. This coverage substantially increased when
IC80 thresholds of 50 μg/ml or higher were considered (Fig J in S1 Text). Therefore maintaining
high in vivo antibody concentrations, in plasma and especially in infected tissues, may be key
in therapeutic settings, and thus the tissue distribution and in vivo pharmacokinetics of indi-
vidual bnAbs will be critical factors. The coverage of viruses by active antibodies naturally
increased with the total number of bnAbs included in a combination, yet even for the best 4
bnAb combination, only 73.5%, 26.5%, and 2.5% of viruses would have either 2, 3, or all 4 anti-
bodies active at a threshold IC80 titer of< 1.0 μg/ml, respectively. From these analyses, it
becomes apparent that inclusion of a bnAb with better overall breadth (such as 10E8, Figs 1
and 5, Fig J in S1 Text) in a combination may be more advantageous than choosing the most
complementary bnAbs with the highest potency. By further analogy to antiretroviral therapy, it
is possible that at least 3 agents simultaneously active against the virus will be critical to avoid
escape. For the prevention of HIV-1 infection, it may not be quite as critical to have multiple
antibodies simultaneously active, as bnAbs at mucosal surfaces need only to block the transmit-
ting virus at the time of exposure. Nonetheless, combinations of at least 2 or 3 bnAbs may pro-
vide an advantage for breadth and potency in preventing infection, and should enhance
coverage against viral quasispecies from a chronically infected donor.
We also considered the impact of bnAb combinations on limiting the extent of incomplete
neutralization of HIV-1 Env pseudoviruses. Combinations with a higher number of bnAbs, in
addition to improving breadth and potency across different viruses, also improved the capacity
to completely neutralize the expressed forms of an Env within a genetically clonal virus popula-
tion (Fig 6, Figs L and O in S1 Text). The experimental data suggests that the resistant sub-pop-
ulations of virions for different bnAbs do not overlap substantially. This complementarity
reduces the extent of incomplete neutralization shown by combinations with higher number of
bnAbs, an important consideration when selecting optimal bnAb combinations for both pre-
vention and treatment of HIV-1 infection. It should be noted that the pseudoviruses utilized in
our study were produced in 293T cell lines, and thus may differ in glycan heterogeneity and
susceptibility to incomplete neutralization compared to viruses derived from primary PBMC.
However, a recent study comparing clonal viruses grown in either 293T or human PBMC
found overall similar trends in levels of incomplete neutralization for individual bnAbs [65].
These data suggest that the complementarity of bnAbs to limit incomplete neutralization will
likely prove to be effective for primary PBMC grown viruses as well.
The slopes of in vitro neutralization curves for individual bnAbs have been shown to exhibit
inherent variability, with bnAbs exhibiting slopes>1.0 predicted to have greater in vivo effi-
cacy than classes of bnAbs having slopes1.0 [71]. The metric instantaneous inhibitory poten-
tial (IIP), which measures the Log10 reduction in infectious events in the presence of drugs/
antibodies, is positively correlated with neutralization curve slopes, in that bnAbs with higher
slopes are predicted to have IIP values that increase faster with concentration [76]. Here we cal-
culated IIP values for best-in-category bnAb combinations as an opportunity to quantitatively
compare their efficacy based on what is seen with antiretroviral drug combinations [75]. Such
a comparison between bnAbs and standard antiretroviral drugs comes with several caveats.
First, Env is much more variable than the targets of most antiretroviral drugs, making it essen-
tial to measure bnAb activity against a large panel of virus variants, whereas IIP values in the
Jilek et al. study were calculated for a single virus. Second, because bnAbs can engage in Fc
receptor-mediated effector functions [77, 78], the overall in vivo efficacy of bnAb combinations
might be greater than the neutralization measured in vitro. Third, since IIP values depend on
the concentration of drug, tissue-wide heterogeneity and pharmacokinetic profiles of bnAbs
will be needed for accurate prediction. With these caveats in mind, we found that IIP values for
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the best 3 and 4 bnAb combinations compare favorably with those of several available antire-
troviral drug combinations, for which an IIP threshold of 5–8 was found to correlate with clini-
cal success [75]. While single bnAbs and 2 bnAb combinations had IIP< 5 for most viruses,
we found that the best 3 and 4 bnAb combinations had median IIP values> 5 at concentration
thresholds of 100 μg/ml and 10 μg/ml, respectively (Fig 7). Thus, using the Jilek et al. criterion,
the 3 and 4 bnAb combinations could lead to favorable clinical outcomes, while single and 2
bnAb combinations are less likely to succeed.
It must be emphasized that the results from our analyses do not imply that other bnAb can-
didates should not be further considered for inclusion in combinations for clinical testing. In
fact V3-glycan bnAbs 10–1074 and PGT121 have either started or will soon initiate phase I
clinical testing, respectively. Our results do, however, suggest favorable bnAb combinations for
future studies, and provide a reasoned way to narrow the otherwise vast array of possible bnAb
combinations. We provide modeling strategies that enable quantitative assessment of the neu-
tralization patterns of combinations of bnAbs using several metrics, to better inform selection
for clinical use. Yet these in vitromeasures and modeling results are just a few of the parame-
ters that must be considered when selecting optimal bnAb candidates. The stability, manufac-
turability, and in vivo pharmacokinetics, tissue distribution, and safety profiles are just a few
additional key parameters that must also be evaluated when moving bnAb candidates forward
in the clinical pipeline.
Our study focused on HIV-1 clade C viruses as the predominant subtype in sub-Saharan
Africa where bnAb clinical efficacy studies will likely be conducted, and is a dominant subtype
globally. Some bnAb combinations may be more effective against other genetic subtypes, as
bnAbs can exhibit variable levels of neutralization breadth among different clades of virus (e.g.
many V3-glycan antibodies exhibit more limited breadth against CRF01_AE viruses, and
CAP256-VRC26.25 has limited breadth against clade B viruses) [17, 32]. Extensive data sets
are available from the testing of individual bnAbs against large standardized panels of viruses
from multiple subtypes, and the BH-model presented here may be utilized to thoroughly inves-
tigate the question of how viral clade impacts optimal bnAb combinations. We are developing
a web-tool, CombiNaber, which will available on the Los Alamos HIV Immunology Database
(http://www.hiv.lanl.gov/content/sequence/COMBINABER/combinaber.html). This tool will
predict bnAb combination neutralization results from single bnAb neutralization data using
either BH or additive models and perform systematic analysis to provide the user with the best
candidate combinations for their panel (S1 Text).
In summary, we have assessed optimal bnAb combinations predicted to have greatest suc-
cess in the prevention and treatment of infection by HIV-1 clade C, taking into account multi-
ple metrics. In addition to evaluating overall potency and breadth, we have also taken into
account the number of active bnAbs within a given combination, the impact of combinations
in limiting the extent of incomplete neutralization, and to calculate the IIP of bnAb combina-
tions. These latter metrics may be of critical importance when considering the use of bnAbs for
the treatment of HIV-1 infection, as they directly relate to confronting the ability of virus to
escape from selective immune pressure. Our results indicate that for both the prevention and
treatment of HIV-1 infection, combinations with higher numbers of bnAbs are advantageous
in providing increased potency, breadth, complete neutralization, and active coverage. Given
the tremendous resources required to take each single bnAb forward into clinical testing, our
results outline important parameters that can inform the selection of bnAbs with the best indi-
cators of success for clinical development, and stresses the importance of considering the
behavior of bnAb combinations early in planning stages.
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Materials and Methods
Study design
This was a non-randomized laboratory study designed to investigate the breadth and potency
of HIV-1 bnAbs against a panel of 200 clade C HIV-1 Env pseudoviruses, and to develop math-
ematical models to predict combinations of 2, 3, or 4 bnAbs that would exhibit enhanced
breadth, potency, extent of complete neutralization, and IIP relative to single bnAbs. Fifteen
recently described bnAbs targeting four distinct epitopes on HIV-1 Env were each tested
against the panel pseudoviruses in vitro to determine IC50 and IC80 titers and MPI. All neutrali-
zation assays were performed in duplicate and without blinding.
Neutralization assays
Neutralizing antibody titers of bnAbs were determined using a luciferase-based assay in TZM.
bl cells (NIH AIDS Research and Reference Reagent Program) as previously described [79, 80].
Unless stated otherwise, starting concentrations of individual bnAbs ranged from 10–50 μg/ml
depending on the available supply at the time of testing. BnAbs were serially diluted seven
times using 5-fold titration series. The concentration range tested for each bnAb is indicated in
Table A in S1 Text. All assays were performed in a laboratory meeting GCLP standards.
Viruses
A panel of 200 clade C HIV-1 Env pseudoviruses was utilized to assess the potency and breadth
of bnAb neutralization activity. Functional Env clones were derived from individuals in acute/
early stages of infection from South Africa (65%), Tanzania (14%), Malawi (11.5%), Zambia
(6.5%), and Botswana (3%) collected over 12 years (1998–2010). All Envs were from heterosex-
ual transmissions except for a single case of breastfeeding transmission. The majority of Envs
exhibit a Tier 2 neutralization phenotype (75%, n = 150), with 1% classified as Tier 1A, 8.5%
classified as Tier 1B, and 15.5% classified as Tier 3 [81]. Pseudovirus stocks were generated via
transfection in 293T/17 cells (ATCC, Manassas, VA) and titrated using TZM.bl cells as previ-
ously described [82].
Antibodies
A panel of 15 particularly broad and potent human monoclonal antibodies was selected based
on prior data from testing against large multiclade panels of HIV-1 pseudoviruses. In some
cases we included somatic variants or newly engineered variants that exhibited enhanced activ-
ity over parental wildtype bnAbs (i.e. 10-1074V, VRC07-523, CAP256-VRC26.25). Impor-
tantly, we included bnAbs that are currently in human clinical trials (VRC01, 3BNC117, 10–
1074) or are advanced candidates for clinical testing (PGT121, 10E8, PGDM1400,
CAP256-VRC26.25). Antibodies were generated in the laboratories of D. Burton at The Scripps
Research Institute (PGT145, PGMD1400, PG9, PGT121, PGT128), M. Nussenzweig at The
Rockefeller University (10–1074, 10-1074V, 3BNC117), or the NIH Vaccine Research Center
(CAP256-VRC26.08, CAP256-VRC26.25, VRC01, VRC07, VRC07-523, VRC13, 10E8).
VRC01 and VRC07 are CD4bs bnAbs of the same lineage [69]. VRC07-523 is an engineered
clonal variant of VRC07 with increased potency and breadth [23]. Of note, VRC07-523 was
made with a two amino acid mutation in the Fc domain (M428L/N424S) to increase affinity
for the FcRn and therefore increase circulating in vivo half-life [83]; these mutations do not
affect antibody-mediated neutralization. VRC13 is a CD4bs antibody that is distinct from the
VRC01-class of antibodies in that it contacts gp120 primarily via CDR binding loops [70]. 10–
1074 and PGT121 are clonal variants from the same donor [17]. 10-1074V is a variant of
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parental 10–1074 in which six complex-type glycan-contacting residues in IgH have been
substituted with those from bnAb PGT121.
Additive and Bliss-Hill models for predicting bnAb combination
neutralization scores
For theoretical derivations of models, see S1 Text. The additive model [60] predicts combina-
tion IC80 as IC80comb ¼ 1=ð1=IC80A þ 1=IC80B þ . . .Þ, where IC80A ; IC80B ; . . . are the single bnAb
scores. The equation for combination IC50 is similar using single bnAb IC50.
The Bliss-Hill model involves estimating single bnAb neutralization curves using Hill func-
tions, f(c) = cm/(km + cm), where c = bnAb concentration, k = IC50, andm = log(4)/[log(IC80)–log
(IC50)]. The combination neutralization, using the Bliss Independence model, is f = 1 − (1 − fA)
(1 − fB)(1 − fC) . . . where fA(c),fB(c),fC(c), . . . are the single bnAb neutralization functions and c is
the bnAb concentration. This equation is solved for the combination IC50/IC80 (we use Brent
algorithm[84, 85] implemented in Scipy [86]). Treatment of single bnAb IC50/IC80 values above
or below experimental thresholds is detailed in the S1 Text.
For combinations with multiple bnAbs targeting the same epitope, the combined neutraliza-
tion function of such bnAbs is calculated using fAðcÞ ¼ ðgA1ðcÞ þ gA2ðcÞ þ . . .Þ=ð1þ gA1ðcÞþ
gA2ðcÞ þ . . .Þ, where gAiðcÞ ¼ fAiðcÞ=ð1 fAiðcÞÞ and fAiðcÞare Hill curves for each of the bnAbs
A1, A2, . . . The Bliss independence model equation is used with the neutralization functions
fA(c),fB(c),fC(c), . . . for each epitope to get neutralization by the combination.
MPI predictions for bnAb combinations
Given the experimental or predicted MPI values for single bnAbs at a given concentration, fA,
fB,fC,. . ., the combination MPI value was predicted as f = 1 − (1 − fA)(1 − fB)(1 − fC) . . .
IIP predictions for bnAb combinations
IIP is defined as IIP = −Log10(1 − f(c)), where f(c) is the neutralization by a single bnAb or
bnAb combination at concentration c. The Hill functions for neutralization by single bnAbs
were calculated from IC50 and IC80 values, or by fitting experimental neutralization curves
(S1 Text). For IIP of combinations, best-fit single bnAb neutralization functions together with
BH model were used.
Statistical analyses
All statistical analyses were performed using the Stats module in Scipy [86]. Non-parametric
tests were preferred and two sided p-values are reported. False discovery rates (q-values) were
calculated by using qvalue package for Python (https://github.com/nfusi/qvalue), based on the
calculations outlined in reference [87].
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